Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia.

Raul Dias Dos Santos FilhoAndrea RuzzaLaurens F ReeskampAlbert WiegmanFrançois MachChristopher E KurtzAndrew HamerIan BridgesAndrea BartuliJean BergeronTamás SzamosiSaikat SantraClaudia StefanuttiOlivier S DescampsSusanne Greber-PlatzerIlse LuirinkJohn J P KasteleinDaniel Gaudetnull null

Published in: The New England journal of medicine (2020)

In this trial involving pediatric patients with familial hypercholesterolemia, evolocumab reduced the LDL cholesterol level and other lipid variables. (Funded by Amgen; HAUSER-RCT ClinicalTrials.gov number, NCT02392559.).

Keyphrases

low density lipoprotein
clinical trial
study protocol
early onset
phase iii
randomized controlled trial
open label